Results 121 to 130 of about 610,359 (296)

CD9‐association with PIP2 areas is regulated by a CD9 salt bridge

open access: yesFEBS Open Bio, EarlyView.
The tetraspanin CD9 has an intracellular salt bridge. If CD9 opens, open‐CD9 moves from PIP2‐rich areas to regions populated by its interaction partner EWI‐2. Hence, the state of the salt bridge regulates the distribution of CD9 and by this CD9‐EWI‐2 complex formation.
Yahya Homsi   +2 more
wiley   +1 more source

Nitric oxide‐forming nitrite reductases in the anaerobic ammonium oxidizer Kuenenia stuttgartiensis

open access: yesFEBS Open Bio, EarlyView.
Anammox bacteria remove fixed nitrogen from their environment via anaerobic ammonium oxidation (anammox) with nitrite as electron acceptor and dinitrogen gas as product. The first anammox step is the conversion of nitrite to nitric oxide by nitrite reductase.
Femke J. Vermeir   +4 more
wiley   +1 more source

BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach   +11 more
wiley   +1 more source

On the primordial black hole mass function for broad spectra

open access: yesPhysics Letters B, 2020
We elaborate on the mass function of primordial black holes in the case in which the power spectrum of the curvature perturbation is broad. For the case of a broad and flat spectrum, we argue that such a mass function is peaked at the smallest primordial
V. De Luca, G. Franciolini, A. Riotto
doaj  

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy